<DOC>
	<DOC>NCT01353469</DOC>
	<brief_summary>Primary Objective: To compare the efficacy of Insuman Comb 25 versus Novolin速 30R on HbA1c reduction during a 24-week treatment period in patients with type 2 diabetes mellitus. Secondary Objectives: - To assess the effects of Insuman Comb 25 versus Novolin速 30R in patients with type 2 diabetes mellitus on fasting plasma glucose (FPG) - To assess the safety and tolerability of Insuman Comb 25 versus Novolin速 30R in patients with type 2 diabetes mellitus</brief_summary>
	<brief_title>Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin速 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy</brief_title>
	<detailed_description>The study duration per patient is about 27 weeks (up to 2 weeks screening + 24 weeks open-label treatment + 1 week follow-up).</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion criteria: Type 2 diabetes mellitus patients, as defined by World Health Organization (WHO), diagnosed for at least 1 year at the time of screening visit who are under premix insulin therapy, with or without oral antidiabetic drug (OAD) Signed written informed consent Exclusion criteria: HbA1c &lt;7% or HbA1c &gt;10% at screening No selfmonitoring of blood glucose within 3 months prior to screening visit Premix insulin treatment for less than 3 months. Insulins other than premix insulin treatment within 3 months prior to screening visit In case of treatment with OAD, treatment with a stable OAD dose and regimen for less than 3 months prior to screening visit The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>